Vitamins and Food Supplements
0 items$0.00

No products in the cart.

LC 500-Medical


LC 500-Medical supplement supplies 500 mg of pure, natural L-carnitine in capsule form.


LC 500-Medical supplement supplies 500 mg of pure, natural L-carnitine in capsule form.


L-carnitine is necessary for fatty acid metabolism and energy production in cardiac and skeletal muscle. It is involved in fatty acid oxidation as part of the carnitine shuttle. L-carnitine shuttles fatty acids from the cytosol (the cell fluid) into the mitochondria (the cell’s powerhouses) for oxidation and energy production. L-carnitine is necessary in muscle whenever fat is utilized as an energy source.*

Heart muscle always uses fat for its continuous energy demands. Skeletal muscle begins using fat only after its glycogen reserves are exhausted. This happens after about one hour of continuous, strenuous exercise, e.g., long-distance running, bicycling, swimming, or mountain climbing. Widely distributed in foods from animal, but not plant sources, L-carnitine is also synthesized by the liver and kidney from two essential amino acids, lysine and methionine. Human skeletal and cardiac muscles contain relatively high L-carnitine concentrations which they receive from plasma, since they are incapable of L-carnitine biosynthesis themselves. About 95 % of the body’s L-carnitine stores are located in skeletal and heart muscle. L-carnitine is considered a conditionally essential nutrient. In healthy people, plasma L-carnitine levels are adequately maintained by the body’s own synthesis and dietary sources. However, low L-carnitine plasma levels can be caused by hereditary (primary) L-carnitine deficiency syndrome, or by secondary L-carnitine deficiency. Patients with heart failure excrete large amounts of L-carnitine in their urine.

Oral L-carnitine is readily absorbed across the intestinal mucosa and into the bloodstream. It is then taken up from the portal vein into the liver and subsequently released into the systemic circulation. Most cells have a specific carnitine transporter. Dietary L-carnitine comes mainly from animal foods. Average non-vegetarian diets provide about 100 to 300 mg of L-carnitine per day. Vegetarian diets often provide only trace amounts, since vegetables, fruits, and cereals are negligible sources of L-carnitine.

Wow factor summary:

Necessary for fatty acid metabolism

Necessary energy production in cardiac and skeletal muscle.

Necessary in muscle whenever fat is utilized as an energy source.

Improves testosterone production when used with acetyl-L-carnitine (men and women need testosterone)

Important in people with heart failure (congestive heart failure (CHF), edema)

We recommend it for patients with fatty liver or obesity


*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease


Supports weight management, heart and muscle function as well as testosterone production.

Each capsule contains:

  • L-Carnitine 500 mg


One to Two capsules per day or as directed by a physician. It is recommended that LC 500 Medical be taken with meals. Capsules may be pulled apart and the powder mixed with food or liquids if desired. Supports Weight Management and Heart and Muscle Function


  • Adamo S, Siliprandi N, Dl Lisa F, Carrara M, Azzurro M, Sartori G, Vita G, Ghidini O. Effect of L-carnitine on ethanol and acetate plasma levels after oral administration of ethanol in humans. Alcohol Clin Exp Res 1988;12:653-4.
  • Arenas J, Huertas R, Campos Y, Diaz AE, Villalon JM, Vilas E. Effects of L-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Lett 1994;341:91-3.
  • Breningstall GN. Carnitine deficiency syndromes. Pediatr Neurol 1990;6:75-81.
  • Brevetti G, di Lisa F, Perna S, Menabo R, Barbato R, Martone VD, Siliprandi N. Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation 1996;93:1685-9.
  • Campos Y, Huertas R, Lorenzo G, Bautista J, Gutierrez E, Aparicio M, Alesso L, Arenas J. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993;16:150-3.
  • Corbucci GG, Lettieri B. Cardiogenic shock and L-carnitine: clinical data and therapeutic perspectives. Int J Clin Pharmacol Res 1991;11:283-93.
  • Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 1992;18:355-65.
  • De los Reyes B, Navarro JA, Perez-Garcia R, Liras A, Campos Y, Bornstein B, Arenas J. Effects of L-carnitine on erythrocyte acyl- CoA, free CoA, and glycerophospholipid acyltransferase in uremia. Am J Clin Nutr 1998;67:386-90.
  • Digiesi V, Cantini F, Bisi G, Guarino G, Brodbeck B. L-carnitine adjuvant therapy in essential hypertension. Clin Ter 1994;144:391-5.
  • Fujiwara M, Nakano T, Tamoto S, Yamada Y, Fukai M, Takada K, Ashida H, Shimada T, Ishihara T, Seki I. [Effect of L-carnitine in patients with ischemic heart disease]. J Cardiol 1991;21:493-504.
  • Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure [published erratum appears in Int J Clin Pharmacol Ther Toxicol 1989 Aug;27(8):418]. Int J Clin Pharmacol Ther Toxicol 1988;26:217-20.
  • Giamberardino MA, Dragani L, Valente R, Di Lisa F, Saggini R, Vecchiet L. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. Int J Sports Med 1996;17:320-4.
  • Goa KL, Brogden RN. l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 1987;34:1-24.
  • Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373-90.
  • Kendler BS. Recent nutritional approaches to the prevention and therapy of cardiovascular disease. Prog Cardiovasc Nurs 1997;12:3-23.
  • Matsui S, Sugita T, Matoba M, Murakami E, Takekoshi N, Shinka T, Matsumoto I. Urinary carnitine excretion in patients with heart failure. Clin Cardiol 1994;17:301-5.
  • Mondillo S, Faglia S, D’Aprile N, Mangiacotti L, Campolo MA, Agricola E, Palazzuoli V. [Therapy of arrhythmia induced by myocardial ischemia. Association of L- carnitine, propafenone and mexiletine]. Clin Ter 1995;146:769-74.
  • Palazzuoli V, Mondillo S, Faglia S, D’Aprile N, Camporeale A, Gennari C. [The evaluation of the antiarrhythmic activity of L-carnitine and propafenone in ischemic cardiopathy]. Clin Ter 1993;142:155-9.
  • Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 1991;13:2-21; discussion 1.
  • Pugliese D, Sabba C, Ettorre G, Berardi E, Antonica G, Godi L, Palasciano G, Lee SS, Albano O. Acute systemic and splanchnic haemodynamic effects of L-carnitine in patients with cirrhosis. Drugs Exp Clin Res 1992;18:147-53.
  • Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 1990;65:755-60.
  • Scholte HR, Luyt-Houwen IE, Vaandrager-Verduin MH. The role of the carnitine system in myocardial fatty acid oxidation: carnitine deficiency, failing mitochondria and cardiomyopathy. Basic Res Cardiol 1987;82:63-73.
  • Scholte HR, Rodrigues Pereira R, Busch HF, Jennekens FG, Luyt-Houwen IE, Vaandrager-Verduin MH. Carnitine deficiency, mitochondrial dysfunction and the heart. Identical defect of oxidative phosphorylation in muscle mitochondria in cardiomyopathy due to carnitine loss and in Duchenne muscular dystrophy. Wien Klin Wochenschr 1989;101:12-7.
  • Siliprandi N, Sartorelli L, Ciman M, Di Lisa F. Carnitine: metabolism and clinical chemistry. Clin Chim Acta 1989;183:3-11.
  • Van Es A, Henny FC, Kooistra MP, Lobatto S, Scholte HR. Amelioration of cardiac function by L-carnitine administration in patients on haemodialysis. Contrib Nephrol 1992;98:28-35.
  • Vecchiet L, Di Lisa F, Pieralisi G, Ripari P, Menabo R, Giamberardino MA, Siliprandi N. Influence of L-carnitine administration on maximal physical exercise [see comments]. Eur J Appl Physiol 1990;61:486-90.

†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


There are no reviews yet.

Be the first to review “LC 500-Medical”

Your email address will not be published. Required fields are marked *